CD8A and melanoma: Compared to terminally exhausted T cells, progenitor exhausted CD8+ TILs are better at controlling tumor growth, melanoma patients with a higher proportion of progenitor exhausted CD8+ TILs have a longer response to PD-1 blockade therapy [84].